Document is current
Any future updates will be listed below
-
Authors
Kimura, Takayuki https://orcid.org/0000-0002-2903-4920
Takami, Tomoko
Piao, Yi
Ntalla, Ioanna
Saji, Shigehira
- License Information
-
More Information
Article History
Received: 1 November 2023
Accepted: 25 January 2024
First Online: 5 May 2024
Declarations
:
: Takayuki Kimura, Tomoko Takami, and Yi Piao are employees of Gilead Sciences K.K. Ioanna Ntalla is employee of Gilead Sciences Europe Ltd. Shigehira Saji received grants to his institution from Taiho Pharmaceutical, Eisai, Chugai Pharmaceutical, Takeda Pharmaceutical, MSD, AstraZeneca, Daiichi Sankyo, and Eli Lilly; received personal fees including honoraria from Chugai Pharmaceutical, Kyowa Kirin, MSD, Novartis Pharma, Eisai, Takeda Pharmaceutical, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho Pharmaceutical, Ono Pharmaceutical, and Nippon Kayaku; is a Member of the Data Safety Monitoring Board/Advisory Board for Chugai Pharmaceutical, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, and Daiichi Sankyo; is an Executive Board Member for JBCRG, JBCS, Japanese Society of Medical Oncology (JSMO), and Breast International Group (BIG).
: No Institutional Review Board (IRB) or Independent Ethics Committee (IEC) review was required for this secondary analysis of existing data.
: Because this research used anonymized processed information, it was outside the scope of the “Ethical Guidelines for Medical and Biological Research Involving Human Subjects” (March 23, 2021).
